hVIVO plc (LON:HVO - Get Free Report) shares were down 46.3% on Friday . The company traded as low as GBX 6.50 ($0.09) and last traded at GBX 8.70 ($0.12). Approximately 83,062,000 shares traded hands during trading, an increase of 2,325% from the average daily volume of 3,424,608 shares. The stock had previously closed at GBX 16.20 ($0.22).
Analyst Upgrades and Downgrades
Separately, Shore Capital reissued a "buy" rating on shares of hVIVO in a report on Friday.
Get Our Latest Research Report on HVO
hVIVO Stock Performance
The company has a market capitalization of £61.56 million, a P/E ratio of 3.59 and a beta of 0.97. The stock has a fifty day simple moving average of GBX 16.16 and a 200-day simple moving average of GBX 18.04. The company has a quick ratio of 1.16, a current ratio of 1.61 and a debt-to-equity ratio of 33.86.
hVIVO (LON:HVO - Get Free Report) last released its quarterly earnings results on Thursday, April 10th. The company reported GBX 1.69 ($0.02) earnings per share (EPS) for the quarter. hVIVO had a return on equity of 47.93% and a net margin of 25.96%. Equities analysts forecast that hVIVO plc will post 1.5492958 EPS for the current year.
Insider Activity at hVIVO
In related news, insider Yamin Mo' Khan sold 3,062,246 shares of hVIVO stock in a transaction dated Thursday, March 6th. The stock was sold at an average price of GBX 17 ($0.23), for a total value of £520,581.82 ($700,648.48). 14.03% of the stock is currently owned by company insiders.
hVIVO Company Profile
(
Get Free Report)
hVIVO plc operates as a pharmaceutical service and contract research company. The company is involved in testing vaccines and antivirals using human challenge clinical trials. It provides services to big pharma, biotech, government, and public health organizations. The company has a portfolio of human challenge study models for conditions, such as RSV, flu, human rhinovirus, asthma, malaria, cough, and COPD, as well as developing COVID-19 human challenge study model.
Featured Articles
Before you consider hVIVO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and hVIVO wasn't on the list.
While hVIVO currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know? MarketBeat just compiled its list of the twelve stocks that corporate insiders are abandoning. Complete the form below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
